<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495662</url>
  </required_header>
  <id_info>
    <org_study_id>LIPMAT</org_study_id>
    <nct_id>NCT02495662</nct_id>
  </id_info>
  <brief_title>The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation</brief_title>
  <acronym>LIPMAT</acronym>
  <official_title>The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HagaZiekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OLVG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Center Haaglanden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reinier de Graaf Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spaarne Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alrijne Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tergooi Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate if liposomal prednisolone is effective in promoting arteriovenous
      fistula (AVF) maturation when administered to human subjects after surgical creation of a
      radio-cephalic AVF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AVFs are the preferred means of vascular access for maintenance hemodialysis. Nonmaturation
      occurs in 30-50% of cases, with highest rates in radio-cephalic fistulas. Inflammatory
      cytokines are involved in this process of nonmaturation. By suppressing inflammation,
      corticosteroids might promote maturation, but have significant systemic side effects.
      Liposomal prednisolone has a long circulation time and targets inflamed tissue with low
      systemic concentrations and limited side effects. In an animal study, it was demonstrated to
      promote AVF maturation. At present, no drug therapy aimed at improving shunt maturation is
      available. This study will investigate if liposomal prednisolone is effective in promoting
      AVF maturation when administered to human subjects after surgical creation of a
      radio-cephalic AVF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cephalic vein diameter</measure>
    <time_frame>6 weeks after surgical creation of the radiocephalic shunt.</time_frame>
    <description>Echographic measurement of the diameter of the cephalic vein, six weeks after surgical creation of the radiocephalic shunt.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cephalic vein diameter</measure>
    <time_frame>3 months after surgical creation of the radiocephalic shunt.</time_frame>
    <description>Echographic measurement of the diameter of the cephalic vein, three months after surgical creation of the radiocephalic shunt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial artery diameter</measure>
    <time_frame>6 weeks after surgical creation of the radiocephalic shunt.</time_frame>
    <description>Echographic measurement of the diameter of the radial artery, six weeks after surgical creation of the radiocephalic shunt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial artery diameter</measure>
    <time_frame>3 months after surgical creation of the radiocephalic shunt.</time_frame>
    <description>Echographic measurement of the diameter of the radial artery, three months after surgical creation of the radiocephalic shunt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial artery flow.</measure>
    <time_frame>6 weeks after surgical creation of the radiocephalic shunt.</time_frame>
    <description>Echographic measurement of the flow of the radial artery, six weeks after surgical creation of the radiocephalic shunt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial artery flow.</measure>
    <time_frame>3 months after surgical creation of the radiocephalic shunt.</time_frame>
    <description>Echographic measurement of the flow of the radial artery, three months after surgical creation of the radiocephalic shunt.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Renal Dialysis</condition>
  <condition>Hemodynamics</condition>
  <condition>Vascular Remodeling</condition>
  <condition>Neointima</condition>
  <arm_group>
    <arm_group_label>Liposomal prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with polyethylene glycol (PEG)-liposomal prednisolone sodium phosphate 150mg in 500ml saline intravenously at 1 and 15 days post surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with 500ml normal 0.9% saline intravenously at 1 and 15 days post surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-liposomal prednisolone sodium phosphate</intervention_name>
    <description>Liposomal prednisolone</description>
    <arm_group_label>Liposomal prednisolone</arm_group_label>
    <other_name>Nanocort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are scheduled for creation of a radiocephalic AVF for maintenance
             hemodialysis.

          2. Male or female â‰¥ 18 years old.

          3. Patients are able and willing to give written informed consent.

        Exclusion Criteria:

          1. Any concurrent illness, disability or clinically significant abnormality that may, as
             judged by the investigator, affect the interpretation of clinical efficacy or safety
             data or prevent the subject from safely completing the assessments required by the
             protocol.

          2. Current participation in another interventional clinical trial or subjects who have
             received an investigational drug within 30 days prior to the baseline visit.

          3. History of psychosis.

          4. History of osteonecrosis

          5. Previous AVF in the ipsilateral arm.

          6. Current central venous catheter at the ipsilateral side.

          7. Treatment with oral, rectal or injectable (including intra-articular) glucocorticoids
             (CS) within 6 weeks prior to baseline visit. Inhaled glucocorticoids are allowed.
             Topical steroids are allowed, however subjects should not have received more than 100
             gram of a mild to moderate topical corticosteroid cream per week, 50 gram of a potent
             corticosteroid cream per week or 30 gram of a very potent topical corticosteroid cream
             per week in the 4 weeks prior to the baseline visit.

          8. Treatment with immunosuppressant drugs. Treatment with non-steroidal anti-inflammatory
             drugs (NSAIDs).

          9. Patients who are unlikely to adequately comply with the trial's procedures (due for
             instance to medical conditions likely to require an extended interruption or
             discontinuation, history of substance abuse or noncompliance).

         10. Women who are lactating, pregnant (positive pregnancy test at baseline) or planning to
             become pregnant during the course of the study.

         11. Unwillingness to use reliable and acceptable contraceptive methods throughout the
             study and till 3 months after last study medication except for female patients who are
             surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)
             or at least 1 year postmenopausal.

         12. Malignant disease, unless cured. Current prostate carcinoma without current or planned
             cytostatic therapy is allowed.

         13. Uncontrolled Diabetes mellitus.

         14. Signs of active infection, requiring systemic treatment.

         15. Positive Quantiferon test.

         16. Subject with positive hepatitis panel (including hepatitis B surface antigen [HBsAg],
             and / or anti-hepatitis B core antibodies, and / or hepatitis C virus antibody
             [anti-HCV]).

         17. History of anaphylaxis or severe allergic responses, including to radio-contrast
             agents.

         18. Planned live-virus vaccinations.

         19. Planned surgical interventions or planned elective hospital admissions within 6 weeks
             after AVF surgery. Planned hemodialysis sessions do not count as an exclusion
             criterion.

         20. Abnormal hepatic function (Alanine aminotransferase (ALT)/ aspartate aminotransferase
             (AST) or bilirubin &gt; 2 x upper limit of normal) at the time of the screening visit.

         21. Clinically significant out-of-range values on hematology panel, at discretion of the
             Principal Investigator.

         22. Current substance abuse or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joris I Rotmans, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joris I Rotmans, MD PhD</last_name>
    <phone>+31715269111</phone>
    <phone_ext>98163</phone_ext>
    <email>j.i.rotmans@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bram M Voorzaat, MD</last_name>
    <phone>+31715269111</phone>
    <phone_ext>ASK</phone_ext>
    <email>b.m.voorzaat@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bram M Voorzaat, MD</last_name>
      <phone>+31-(0)71-5269111</phone>
      <phone_ext>ASK</phone_ext>
      <email>b.m.voorzaat@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Joris I Rotmans, MD, PhD</last_name>
      <phone>+31-(0)71-5269111</phone>
      <phone_ext>98163</phone_ext>
      <email>j.i.rotmans@lumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Bram M Voorzaat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joris I Rotmans, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>JorisRotmans</investigator_full_name>
    <investigator_title>J.I. Rotmans, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Vascular access</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Arteriovenous shunt</keyword>
  <keyword>Arteriovenous fistula</keyword>
  <keyword>Maturation</keyword>
  <keyword>Liposomal prednisolone</keyword>
  <keyword>PEG-liposomal prednisolone sodium phosphate</keyword>
  <keyword>Radio-cephalic</keyword>
  <keyword>Shunt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Neointima</mesh_term>
    <mesh_term>Vascular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

